Position in CHRS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$81,522
New position
Shares Held
58,230
first reported quarter
Ownership
0.038%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#60
of 147 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Canton Hathaway, LLC holds $783,315 across 6 Biotechnology names. CHRS ranks #4 (10.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BHVN |
Biohaven Ltd.
|
22,600 | $336,288 | |
| 2 | INCY |
Incyte Corp
|
1,500 | $170,040 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
1,000 | $122,580 | |
| 4 | CHRS |
Coherus Oncology, Inc.
This page
|
58,230 | $81,522 | |
| 5 | MRNA |
Moderna, Inc.
|
601 | $42,088 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
62 | $30,797 |
All Filings in CHRS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $81,522 | 58,230 | Shares | Sole | 2026-08-06 | |
| No filing history on record for this holder in this stock. | ||||||